ACTU - NASDAQ

AT

Actuate Therapeutics Inc

ACTU·NASDAQ

$2.11

-4.5%
HealthcareBiotechnology

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$50.48M
EPS-1.0600
P/E Ratio-5.79
Earnings Date06/03/2026

actu

Shares Outstanding

Last Annual Value

21.02M

3-Year CAGR

12%

5-Year CAGR

7%

10-Year CAGR

3%

AT

Actuate Therapeutics Inc Competitors Analysis of shares-outstanding

ACTU · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
ACTU logo
Actuate Therapeutics Inc
NASDAQ:ACTU
21.02M
11.8%N/AN/A 
CRDF logo
Cardiff Oncology, Inc.
NASDAQ:CRDF
66.84M
14.4%11.4%66.0%
FATE logo
Fate Therapeutics, Inc.
NASDAQ:FATE
118.79M
6.5%4.6%14.1%
FBRX logo
Forte Biosciences, Inc.
NASDAQ:FBRX
147.18M
388.5%204.9%121.1%
SPRO logo
Spero Therapeutics, Inc.
NASDAQ:SPRO
59.04M
3.7%13.8%24.5%
ELTX logo
Elicio Therapeutics, Inc.
NASDAQ:ELTX
15.31M
44.7%36.8%N/A
MCRB logo
Seres Therapeutics, Inc.
NASDAQ:MCRB
8.87M
11.5%14.1%-13.9%
APLT logo
Applied Therapeutics, Inc.
NASDAQ:APLT
139.53M
18.3%40.4%N/A
ALEC logo
Alector, Inc.
NASDAQ:ALEC
103.00M
7.1%5.1%28.3%
VTGN logo
VistaGen Therapeutics, Inc.
NASDAQ:VTGN
30.71M
64.0%60.6%86.9%
NKTX logo
Nkarta, Inc.
NASDAQ:NKTX
73.99M
14.7%17.6%N/A
AT

Actuate Therapeutics Inc Fair Value Envelope

ACTU · NASDAQ

Our analysis suggests that ACTU has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.11, this represents a potential HIDDEN relative to our calculated worth for Actuate Therapeutics Inc.

HIDDEN
Intrinsic Value
Current Price: $2.11

Related Guides

Blog Categories

Continue your ACTU research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.